Literature DB >> 20302850

Hippocampal expression and distribution of CB1 receptors in the Amazonian rodent Proechimys: an animal model of resistance to epilepsy.

Bruno Henrique Silva Araujo1, Laila Brito Torres, Ana Carolina Cossa, Maria da Graça Naffah-Mazzacoratti, Esper Abrão Cavalheiro.   

Abstract

Proechimys, a rodent living in the Amazon region, has shown resistance to developing chronic epilepsy when submitted to different experimental models. Recently, many studies have attributed a potent anticonvulsant action to cannabinoid receptor CB1. This study investigated the distribution and expression of the CB1 receptor in the hippocampal formation of Proechimys using immunohistochemistry and Western blotting techniques. Results were compared with values obtained from adult Wistar rats. The immunoreactivity for CB1 was evident throughout the Ammon's horn and in the hilar region of both animal species. However, the distribution of these receptors was higher in the stratum lucidum of CA3 and in the hilar region of Proechimys. In addition, higher expression of CB1 receptors was observed in the Proechimys hippocampus. These data could explain, at least partially, the natural resistance of this animal species to developing spontaneous seizures following epileptogenic precipitating events. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20302850     DOI: 10.1016/j.brainres.2010.03.031

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain.

Authors:  Katherine W Sayers; Peter T Nguyen; Robert E Blair; Laura J Sim-Selley; Robert J DeLorenzo
Journal:  Epilepsia       Date:  2012-04-17       Impact factor: 5.864

2.  Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.

Authors:  Vinogran Naidoo; David A Karanian; Subramanian K Vadivel; Johnathan R Locklear; JodiAnne T Wood; Mahmoud Nasr; Pamela Marie P Quizon; Emily E Graves; Vidyanand Shukla; Alexandros Makriyannis; Ben A Bahr
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

3.  A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity.

Authors:  Vinogran Naidoo; Spyros P Nikas; David A Karanian; Jeannie Hwang; Jianhong Zhao; JodiAnne T Wood; Shakiru O Alapafuja; Subramanian K Vadivel; David Butler; Alexandros Makriyannis; Ben A Bahr
Journal:  J Mol Neurosci       Date:  2010-11-11       Impact factor: 3.444

4.  Endocannabinoids and diacylglycerol kinase activity.

Authors:  Arpita Gantayet; Januvi Jegatheswaran; Gowtham Jayakumaran; Matthew K Topham; Richard M Epand
Journal:  Biochim Biophys Acta       Date:  2010-12-29

5.  Characterization of the sleep-wake cycle of the Neotropical rodent Proechimys guyannensis.

Authors:  José Cláudio da Silva; Gabriela de Matos Barbosa Pimenta; Monica Levy Andersen; Gerhardus Hermanus Maria Schoorlemmer; Sérgio Tufik; Esper Abrão Cavalheiro
Journal:  SAGE Open Med       Date:  2014-07-22

Review 6.  Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies.

Authors:  Sheila Garcia-Rosa; Bianca de Freitas Brenha; Vinicius Felipe da Rocha; Ernesto Goulart; Bruno Henrique Silva Araujo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.